TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05812521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral block with methylene blue
Description: The paravertebral space is identified under ultrasound guidance and after negative aspiration a 3 ml test dose of anesthetic is injected. After observing widening of the paravertebral space and anterior pleural displacement to confirm the correct needle positioning, a bolus dose of 20 mL 0.5% ropivacaine with a solution of 1 ml 1% methylene blue and 4 ml of saline will be injected in the paravertebral space. At the start of the surgery, the spread of the solution of anesthetic and methylene blue will be assessed through visualization in thoracoscopy and if necessary the block will be repeated. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
Study: NCT00774605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline free base solution
Description: A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline free base patch
Description: A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
Study: NCT05812521

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural Anesthesia
Description: The epidural catheter will be placed using the loss of resistance technique, and after ruling out intravenous or intrathecal catheter placement with a negative aspiration test dose, an initial dose of 10 mL 0.25% bupivacaine will be injected. Continuous infusion will be started with with 0.125 % bupivacaine + fentanyl 0.5 mcg/ ml at 6-10 ml/hour will be started based on the patient weight for 48 hours postoperatively. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
Study: NCT02984033

Intervention type: RADIATION
Intervention: Head and Neck patients
Description: Treatment consists of Intensity Modulated Radiation Therapy (until 2.2 Gy) with a total dose of 50-66 Gy in post-operative setting and 66-72 Gy in radical setting.
Study: NCT02410109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCRIPT integrated model
Description: Perinatal women will be screened for psychosocial risks at time of home visiting enrollment. Women exhibiting elevated depressive symptoms and/or have a history of clinical depression who are not currently clinically depressed will be referred for depression prevention services. Women experiencing a depressive episode will be referred for group CBT. Women who screen positive for elevated anxiety symptoms, PTSD symptoms, intimate partner violence, or substance abuse will be referred to a mental health or social service agencies. If a client is referred for services, the assessment worker will provide written educational materials about the risk factor that is being addressed through the referral. At the first home visit, the home visitor will discuss these educational materials.
Study: NCT02384122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Two injections of 20 mg will be given monthly.
Study: NCT02313194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Stimulation
Description: Determine if epidural stimulation can improve motor function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Determine if the pharmacological agent in combination with the stimulator can improve motor function.
Study: NCT03139045

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Venous puncture in elderly patients
Description: Venous puncture in elderly patients

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Venous puncture in elderly patients
Description: Venous puncture in elderly patients
Study: NCT02256826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: NORVIR®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: NORVIR®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra®
Description: (lopinavir (LPV) and ritonavir (RTV))
Study: NCT02267109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z
Description: IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z
Description: IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z
Description: IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z
Description: IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Booster-MVA-BN® Filo or saline placebo
Description: IM injection of Booster-MVA-BN® Filo or saline placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Booster-MVA-BN® Filo or saline placebo
Description: IM injection of Booster-MVA-BN® Filo or saline placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Booster-MVA-BN® Filo or saline placebo
Description: IM injection of Booster-MVA-BN® Filo or saline placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Booster-MVA-BN® Filo or saline placebo
Description: IM injection of Booster-MVA-BN® Filo or saline placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Booster-MVA-BN® Filo or saline placebo
Description: IM injection of Booster-MVA-BN® Filo or saline placebo
Study: NCT01724021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1400 mg subcutaneously (SC), Day 1 Cycles 2-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV, Day 1 Cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1400 mg SC, Day 1 Cycles 5-8
Study: NCT00164515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized exercise programme (PEP)
Description: Physician referred overweight and obese clients to 24 month personalized exercise programme at the U. of Illinois, Chicago

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized exercise programme (PEP)
Description: Physician referred overweight and obese clients to 24 month personalized exercise programme at the U. of Illinois, Chicago
Study: NCT05850338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cold pad pillow
Description: cold pad pillow application when women have vasomotor symptoms for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: autogenic training
Description: Autogenic relaxation for three times a day for eight weeks
Study: NCT01853605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped silicone gel-filled breast implants
Description: Surgical implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped silicone gel-filled breast implants
Description: Surgical implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped silicone gel-filled breast implants
Description: Surgical implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped silicone gel-filled breast implants
Description: Surgical implant
Study: NCT03249987

Intervention type: OTHER
Group type: OTHER
Intervention: bladder diary
Description: electronic diary to be completed for 3 days before crossover onto paper diary for 3 days

Intervention type: OTHER
Group type: OTHER
Intervention: bladder diary
Description: electronic diary to be completed for 3 days before crossover onto paper diary for 3 days
Study: NCT02238860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entacavir
Description: Entacavir-0.5 mg ,OD,for

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entacavir
Description: Entacavir-0.5 mg ,OD,for

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir ,300 mg,OD,for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir ,300 mg,OD,for 48 weeks
Study: NCT02272166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study: NCT04557046

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal Swab
Description: Collection of one more nasal swabs

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal Swab
Description: Collection of one more nasal swabs
Study: NCT02164305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening group
Description: Open-chain exercise for rotator cuff and scapular muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular group
Description: Closed-chain exercise for shoulder muscles
Study: NCT04557046

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal Swab
Description: Collection of one more nasal swabs

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal Swab
Description: Collection of one more nasal swabs

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: Collection of one more nasopharyngeal swabs

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Throat swab
Description: Collection of one more throat swabs

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fingerstick
Description: Collection of capillary blood from one or more fingersticks

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Saliva specimen
Description: Collection of free drool

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Saliva specimen
Description: Collection of free drool
Study: NCT02903121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen (open label)
Description: Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the second 90 days of the study
Study: NCT02003287

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VFSS
Description: Videofluoroscopic Swallow Study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FEES
Description: Fiberoptic Endoscopic Swallow Study
Study: NCT02791841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Reading Training
Description: RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
Study: NCT04557046

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Saliva specimen
Description: Collection of free drool
Study: NCT02791841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Hemispheric-Specific Stimulation + Action Video Games
Description: This training combines Visual Hemisphere-Specific Stimulation (VHSS) according to Bakker's Balance Model, and Action Video-Games (AVG). Hemispheric-specific stimulation is carried out by tachistoscopic presentation of words to a visual hemifield in order to selectively stimulate right-hemisphere perceptual analysis or left-hemisphere linguistic anticipation. A computerized program is used, in which the word is flashed and presented for less than 350 ms only if the child clicks on the mouse at the exact moment a dot is crossing a central target (control of eye position and fixation).~AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Video Games
Description: AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used.
Study: NCT02461160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching TAK-915 suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915 tablet
Description: TAK-915 tablet
Study: NCT04174612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 100 mg/m2/bid day 1-3 100 mg/m2/die day 4-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: 60 mg/m2/die day 1-3
Study: NCT04185389

Intervention type: OTHER
Intervention: HPV and cytology co-testing (via Liquid based collection device)
Description: Liquid-based cytology co-testing is a procedure in which that a cervical sample is taken, and can be co-tested for HPV and standard cytology at the same time. It is collected in the same way that a traditional Pap is collected
Study: NCT04174612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: 60 mg/m2/die day 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: 50 mg/bid day 8-21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midostaurin
Description: 50 mg/bid day 8-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine HD
Description: 100 mg/m2/bid day 1-3 100 mg/m2/die day 4 1.500 mg bid day 5-7
Study: NCT01748058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise based on active video gaming
Study: NCT03153423

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Strabismus surgery
Description: Recession and resection of horizontal extra ocular muscles
Study: NCT02290405

Intervention type: BEHAVIORAL
Intervention: Multiple Sleep Latency Test (MSLT)
Description: The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.

Intervention type: BEHAVIORAL
Intervention: Multiple Sleep Latency Test (MSLT)
Description: The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.
Study: NCT01776255

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Children, Strong Families
Description: Healthy Children, Strong Families is a series of 13 lessons mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Children, Strong Families
Description: Healthy Children, Strong Families is a series of 13 lessons mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child Safety
Description: The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Safety
Description: The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.
Study: NCT01288404

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorometholone
Description: topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: subconjunctival bevacizumab 1.25 mg/0.05mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: subconjunctival bevacizumab 2.5 mg/0.1mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: subconjunctival bevacizumab 3.75 mg/0.15mL
Study: NCT02323828

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High RS cookies
Description: High RS cookies ingestion in healthy young adults

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cookies ingestion in healthy young adults
Study: NCT01561846

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CLA enriched cheese
Description: This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CLA enriched cheese
Description: This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CLA enriched cheese
Description: This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
Study: NCT02892552

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography (CBCT)
Description: Patients had an additional Cone Beam Computed Tomography, after the usual MDCT